# FibroBiologics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/FibroBiologics, Inc.). ## Overview FibroBiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based cell therapies for chronic diseases with high unmet medical need. Its pipeline includes CYWC628, CYPS317, CYMS101 and CybroCell™, with programs aimed at wound healing, autoimmune disease, degenerative disc disease, psoriasis, certain cancers and potential longevity applications. ## Products & services • CYWC628 fibroblast cell therapy for diabetic foot ulcers • CYPS317 product candidate for psoriasis • CYMS101 product candidate for multiple sclerosis • CybroCell™ fibroblast-based drug product platform • Preclinical and clinical development of fibroblast therapies - **Lead cell therapy candidates** (0%) — Clinical and preclinical fibroblast-based therapies targeting specific diseases such as diabetic foot ulcers, psoriasis and MS. - **Platform technology** (0%) — The underlying fibroblast cell platform and related intellectual property used to generate multiple product candidates. - **Research and development** (100%) — Internal discovery, preclinical studies, clinical trial preparation and regulatory work for the pipeline. - CYWC628 fibroblast therapy for wound healing and diabetic foot ulcers - CYPS317 for psoriasis - CYMS101 for multiple sclerosis - CybroCell™ fibroblast-based drug product platform - Preclinical and clinical development services for internal pipeline ## Customers FibroBiologics does not yet sell commercial products; its near-term 'customers' are clinical trial participants, investigators, CDMOs and regulators that enable development. If approved, its therapies would be sold to healthcare providers, hospitals and specialty treatment centers serving patients with chronic diseases and difficult-to-heal conditions. - **Clinical trial ecosystem** (primary) — Patients, investigators, CROs and CDMOs involved in running preclinical work and clinical trials for the pipeline. - **Wound care providers** (secondary) — Hospitals and wound-care clinics that would use CYWC628 if approved for diabetic foot ulcers and related wounds. - **Specialty physicians** (secondary) — Dermatologists, neurologists and other specialists who could prescribe future approved therapies for psoriasis or MS. - **Regulatory authorities** (primary) — FDA and other agencies that must clear INDs and approve trials and eventual commercialization. - Clinical trial patients enrolled in fibroblast therapy studies - Hospitals and wound-care centers for diabetic foot ulcer treatment - Dermatology and neurology specialists if programs reach market - CDMOs and CROs that support manufacturing and trials - Regulators such as the FDA and foreign agencies for approvals ## Geography The company is headquartered in the United States and conducts most corporate, R&D and financing activity there. Its disclosed clinical development footprint is international, with a planned CYWC628 Phase 1/2 trial in Australia and FDA interactions in the United States. - **United States** (100%) — Corporate headquarters, financing, R&D and regulatory activity - United States is the corporate and regulatory base - Australia is the planned site for the CYWC628 Phase 1/2 trial - FDA oversight is central for CybroCell™ and U.S. development - Manufacturing is outsourced to third-party CDMOs - No revenue geography disclosed because the company has no product sales ## Strategy FibroBiologics is focused on advancing its fibroblast platform through clinical proof-of-concept, starting with CYWC628 and expanding into additional indications. Near term, the company is prioritizing manufacturing readiness, trial execution and IP protection while relying on external capital and strategic collaborations to fund development. - **Clinical advancement of CYWC628** (short-term) — A successful diabetic foot ulcer trial would validate the platform and de-risk later programs. - **Manufacturing readiness** (short-term) — Cell therapy supply depends on reliable CDMO execution and sterility/process control. - **Platform expansion** (medium-term) — Multiple indications improve the odds that at least one program reaches commercialization. - **Capital formation** (short-term) — The company has no product revenue and needs external funding to continue development. - Advance CYWC628 into and through Phase 1/2 testing - Resolve manufacturing process issues before clinical supply - Expand the fibroblast platform into multiple indications - Protect and extend the intellectual property portfolio - Seek external funding and strategic collaborations - Evaluate in-house manufacturing only after commercialization ## Risks The company is pre-revenue, has a limited operating history and depends on successful clinical development, regulatory approval and financing to continue as a going concern. Its biggest execution risks are manufacturing complexity, sterility/process failures, clinical setbacks and the possibility that larger biotech and pharma competitors reach the market first. - **Going concern and funding risk** [critical] — The company has incurred losses since inception and needs substantial additional capital to fund trials and operations. - **Manufacturing and sterility risk** [high] — Cell therapy production requires tight process control; the company already experienced timeline extensions from process issues. - **Clinical development risk** [high] — Programs may fail to show safety or efficacy, which would prevent approval and commercialization. - **Competitive displacement** [high] — Large pharma and biotech firms have greater resources and may commercialize competing therapies first. - **Commercialization capability gap** [medium] — The company has no sales force or distribution network and would need partners or new capabilities post-approval. - No product revenue yet, so survival depends on external financing - Cell therapy manufacturing is complex and prone to sterility/process issues - Clinical trials may fail, delay or produce insufficient efficacy data - Large competitors may develop superior or faster-to-market therapies - Regulatory approvals are uncertain across FDA and foreign agencies - No in-house sales or distribution capability if products are approved ## Accounting Because FibroBiologics is pre-revenue and R&D intensive, reported results are driven mainly by expense recognition rather than sales timing. Investors should watch how it capitalizes or expenses prepayments, values stock-based compensation, and accounts for lease and contract commitments tied to labs and offices. - **R&D expense recognition** — Quarterly operating loss volatility - **Prepaid R&D and manufacturing deposits** — Timing of expense recognition - **Stock-based compensation** — Operating expense and net loss - **Lease commitments** — Cash burn and contractual obligations - No product revenue yet, so results are dominated by R&D and G&A expenses - R&D is expensed as incurred, affecting quarterly loss volatility - Prepaid research and manufacturing deposits are expensed when services are received - Stock-based compensation can materially affect operating expense - Office and lab leases create recurring commitments and IFRS/GAAP lease accounting impact --- *Last updated: 2026-04-28T20:07:57.772979+00:00*